ABSTRACT

Conclusion:

Latanoprost, bimatoprost and travoprost were effective to reduce IOP in POAG and OH patients. Mean difference between pre and post treatment IOP and diurnal variation was similar with the three drops. Ocular adverse effects seem to be more frequent with bimatoprost.

Results:

Mean difference between pre and 6th month treatment IOP with latanoprost, bimatoprost and travoprost was; 9.17 (%39.02±8.21), 9.12 (%38.24±7.57) and 8.28 (%34.63±8.84) mmHg respectively. The difference was statistically significant in all the three groups (p<0.001). The diurnal variation was similar at the three groups (3.05, 3.23, 3.91 mmHg). There was no significant difference between the groups in terms of mean difference between pre and post treatment IOP and diurnal variation (p<0.001). Systemic adverse effect was not observed in any group. Mild and moderate conjunctival hyperemia was observed in 10 eyes (29.4%) with latanoprost, 17 eyes (50%) with bimatoprost and 13 eyes (37.1%) with travoprost. Pigmentation and hyperemia of eyelids was observed in 3 eyes (8.8%) with bimatoprost. Ocular irritation was observed in 1 eye (2.9%) with latanoprost, 4 eyes (11.8%) with bimatoprost and 2 eyes (5.7%) with travoprost. Pigmentation of eyelids and hyperemia of eyelids was observed in 2 different eyes (5.7%) with bimatoprost.

Methods:

In this prospective study, 103 eyes of 62 patients who were followed with the diagnosis of PAAG or OH between August 2003 and May 2004 were included. Eyes with an IOP of 22-34 mmHg, with early diagnosis of PAAG or OH, without any treatment were randomly selected into 3 groups. First group (34 eyes) treated with latanoprost (0.005%), second group (34 eyes) treated with bimatoprost (0.003%) and third group (35 eyes) treated with travoprost (0.004%).

Purpose:

To compare the intraocular pressure (IOP) lowering effect, diurnal variation and adverse effects of latanoprost, bimatoprost, and travoprost in patients with primary open-angle glaucoma (POAG) or ocular hypertension (OH).